



United Research Laboratories, Inc.  
Mutual Pharmaceutical Company, Inc.

1100 Orthodox Street  
Philadelphia, PA 19124  
215-288-6500  
www.urlmutual.com

5699 01 MAR 20 P3:58

March 12, 2001

Dockets Management Branch  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Docket Number 01P-0117**

Dear Sir or Madam:

I have received your letter notifying me that my Citizen Petition was accepted for filing and was assigned the above-referenced docket number. In that letter you characterized the intent of my petition as "to rescind approval of any ANDA for a generic version of a solid oral dosage form of Metaxalone." My petition is similarly characterized on the Docket Management Branch's web page.

Please be advised that this is not an accurate representation of my petition. Specifically, my petition requests the following:

1. Rescind the previous FDA determination that Metaxalone Tablets do not pose a bioequivalence problem, and
2. Require acceptable results from an *in-vivo* fasting bioequivalence study as a condition of approval for any ANDA for a generic version of Metaxalone Tablets.

Please correct your files and your web page in order to avoid confusion as to the issues involved with this petition.


Thank you.

Sincerely,

Robert Dettery  
Vice President, Regulatory Affairs  
Mutual Pharmaceutical Company

DIP-0117

CR1



# FIRST CLASS MAIL

**Mutual Pharmaceutical Company**  
**1100 Orthodox St., Philadelphia, PA 19106**

TO: Dockets Management Branch  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

